Equities research analysts forecast that VIVUS, Inc. (NASDAQ:VVUS) will announce ($0.13) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for VIVUS’s earnings. VIVUS reported earnings of ($0.09) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 44.4%. The company is expected to report its next quarterly earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that VIVUS will report full year earnings of ($0.39) per share for the current financial year. For the next year, analysts expect that the firm will report earnings of ($0.45) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for VIVUS.

Separately, Zacks Investment Research upgraded VIVUS from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Thursday, July 27th.

A number of large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in VIVUS by 41.2% in the first quarter. Renaissance Technologies LLC now owns 6,182,454 shares of the biopharmaceutical company’s stock worth $6,924,000 after buying an additional 1,805,100 shares during the period. AJO LP purchased a new position in VIVUS during the second quarter valued at $3,329,000. Acadian Asset Management LLC boosted its position in VIVUS by 70.9% in the second quarter. Acadian Asset Management LLC now owns 1,837,822 shares of the biopharmaceutical company’s stock valued at $2,241,000 after buying an additional 762,392 shares during the last quarter. OxFORD Asset Management LLP boosted its position in VIVUS by 58.2% in the second quarter. OxFORD Asset Management LLP now owns 929,511 shares of the biopharmaceutical company’s stock valued at $1,134,000 after buying an additional 341,976 shares during the last quarter. Finally, Oxford Asset Management boosted its position in VIVUS by 76.6% in the first quarter. Oxford Asset Management now owns 587,535 shares of the biopharmaceutical company’s stock valued at $658,000 after buying an additional 254,912 shares during the last quarter. Institutional investors and hedge funds own 35.47% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/14/zacks-brokerages-expect-vivus-inc-nasdaqvvus-to-post-0-13-earnings-per-share.html.

Shares of VIVUS (VVUS) traded up 0.99% during midday trading on Monday, hitting $1.02. 206,813 shares of the stock traded hands. The firm’s 50 day moving average price is $1.18 and its 200 day moving average price is $1.12. VIVUS has a 12-month low of $0.99 and a 12-month high of $1.47. The company has a market capitalization of $107.93 million, a PE ratio of 3.29 and a beta of 0.86.

VIVUS Company Profile

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Get a free copy of the Zacks research report on VIVUS (VVUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.